JP2018508516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508516A5 JP2018508516A5 JP2017546075A JP2017546075A JP2018508516A5 JP 2018508516 A5 JP2018508516 A5 JP 2018508516A5 JP 2017546075 A JP2017546075 A JP 2017546075A JP 2017546075 A JP2017546075 A JP 2017546075A JP 2018508516 A5 JP2018508516 A5 JP 2018508516A5
- Authority
- JP
- Japan
- Prior art keywords
- eribulin
- breast cancer
- medicament
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128373P | 2015-03-04 | 2015-03-04 | |
| US62/128,373 | 2015-03-04 | ||
| US201562264068P | 2015-12-07 | 2015-12-07 | |
| US62/264,068 | 2015-12-07 | ||
| PCT/US2016/020734 WO2016141209A1 (en) | 2015-03-04 | 2016-03-03 | Combination of a pd-1 antagonist and eribulin for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508516A JP2018508516A (ja) | 2018-03-29 |
| JP2018508516A5 true JP2018508516A5 (enExample) | 2019-04-18 |
| JP6951248B2 JP6951248B2 (ja) | 2021-10-20 |
Family
ID=55586425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546075A Active JP6951248B2 (ja) | 2015-03-04 | 2016-03-03 | がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10945990B2 (enExample) |
| EP (1) | EP3265122B1 (enExample) |
| JP (1) | JP6951248B2 (enExample) |
| KR (1) | KR20170122810A (enExample) |
| CN (1) | CN107810013B (enExample) |
| AU (1) | AU2016226157B2 (enExample) |
| BR (1) | BR112017018872A2 (enExample) |
| CA (1) | CA2978311A1 (enExample) |
| IL (1) | IL254133B (enExample) |
| MX (1) | MX386547B (enExample) |
| RU (1) | RU2737216C2 (enExample) |
| SG (1) | SG11201706872SA (enExample) |
| WO (1) | WO2016141209A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2522663T3 (pl) | 2004-06-03 | 2015-08-31 | Eisai R&D Man Co Ltd | Produkty pośrednie do otrzymywania halichondryny B |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| HRP20161157T1 (hr) | 2009-03-30 | 2016-11-18 | Eisai R&D Management Co., Ltd. | Liposomski pripravak |
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| KR20170122810A (ko) | 2015-03-04 | 2017-11-06 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| CN107921018A (zh) * | 2015-06-11 | 2018-04-17 | 生态有限公司 | 药物组合及其应用 |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| WO2017188350A1 (ja) | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| EP3525818A1 (en) * | 2016-10-14 | 2019-08-21 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer |
| EP3528834A4 (en) * | 2016-10-21 | 2020-07-01 | Merck Sharp&Dohme Corp. | TREATMENT OF CANCER USING A COMBINATION OF A PD-1 ANTAGONIST AND AN IL-27 ANTAGONIST |
| EP3654967A4 (en) * | 2017-07-21 | 2021-04-21 | Eisai R&D Management Co., Ltd. | USE OF EIBULIN AND CYCLINE-DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER |
| EP3713565A1 (en) | 2017-11-20 | 2020-09-30 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| AU2019285640A1 (en) | 2018-06-15 | 2021-01-21 | Board Of Regents Of The University Of Texas System | Methods of treating and preventing breast cancer with S-equol |
| AU2019285641A1 (en) | 2018-06-15 | 2021-04-08 | The Board Of Regents Of The University Of Texas System | Methods of treating and preventing melanoma with s-equol |
| US11083705B2 (en) * | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| JP2022553421A (ja) * | 2019-10-28 | 2022-12-22 | エンジーケム ライフサイエンシーズ コーポレーション | がんの処置のための方法および組成物 |
| WO2025049528A1 (en) * | 2023-08-29 | 2025-03-06 | Cullinan Amber Corp. | Combination therapies for cancer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| HU227912B1 (en) | 1998-06-17 | 2012-05-29 | Eisai R & D Man Co | Halichondrin analogs and methods of their use and preparation |
| EP1135415B1 (en) | 1998-12-01 | 2010-08-11 | Facet Biotech Corporation | Humanized antibodies to gamma-interferon |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトｐｄ−１に対し特異性を有する物質 |
| PL2522663T3 (pl) | 2004-06-03 | 2015-08-31 | Eisai R&D Man Co Ltd | Produkty pośrednie do otrzymywania halichondryny B |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| CN108948039B (zh) | 2007-10-03 | 2021-12-31 | 卫材R&D管理有限公司 | 用于合成软海绵素b类似物的中间体和方法 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| CN102803254B (zh) | 2010-01-26 | 2016-09-14 | 卫材R&D管理有限公司 | 用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物 |
| EP2680839A1 (en) | 2011-03-02 | 2014-01-08 | Morphotek, Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| WO2012129100A1 (en) * | 2011-03-18 | 2012-09-27 | Eisai R&D Management Co., Ltd. | Methods and compositions for predicting response to eribulin |
| MX341076B (es) | 2011-03-31 | 2016-08-04 | Merck Sharp & Dohme | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. |
| EP2739358B1 (en) | 2011-08-01 | 2018-11-28 | F.Hoffmann-La Roche Ag | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| MX2015007185A (es) | 2012-12-04 | 2017-09-05 | Eisai R&D Man Co Ltd | Uso de eribulina en el tratamiento de cancer de pecho. |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| PT2970473T (pt) * | 2013-03-14 | 2017-10-26 | Bristol Myers Squibb Co | Combinação de agonista de dr5 e antagonista anti-pd-1 e métodos de utilização |
| WO2014193898A1 (en) * | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| US20160120871A1 (en) | 2013-06-11 | 2016-05-05 | Novartis Ag | Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent |
| AU2014299699B2 (en) | 2013-06-26 | 2019-10-10 | Eisai R&D Management Co., Ltd. | Use of eribulin and lenvatinib as combination therapy for treatment of cancer |
| US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
| CA2935423C (en) * | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| EP3114144A1 (en) | 2014-03-05 | 2017-01-11 | Bristol-Myers Squibb Company | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| JP2017516802A (ja) | 2014-05-28 | 2017-06-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がんの治療におけるエリブリンの使用 |
| KR20170122810A (ko) | 2015-03-04 | 2017-11-06 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합 |
-
2016
- 2016-03-03 KR KR1020177027617A patent/KR20170122810A/ko not_active Ceased
- 2016-03-03 BR BR112017018872A patent/BR112017018872A2/pt not_active IP Right Cessation
- 2016-03-03 SG SG11201706872SA patent/SG11201706872SA/en unknown
- 2016-03-03 RU RU2017132877A patent/RU2737216C2/ru active
- 2016-03-03 US US15/554,540 patent/US10945990B2/en active Active
- 2016-03-03 JP JP2017546075A patent/JP6951248B2/ja active Active
- 2016-03-03 MX MX2017011206A patent/MX386547B/es unknown
- 2016-03-03 EP EP16710891.9A patent/EP3265122B1/en not_active Revoked
- 2016-03-03 AU AU2016226157A patent/AU2016226157B2/en not_active Ceased
- 2016-03-03 CA CA2978311A patent/CA2978311A1/en not_active Abandoned
- 2016-03-03 CN CN201680025588.3A patent/CN107810013B/zh not_active Expired - Fee Related
- 2016-03-03 WO PCT/US2016/020734 patent/WO2016141209A1/en not_active Ceased
-
2017
- 2017-08-24 IL IL254133A patent/IL254133B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| JP2018512391A5 (enExample) | ||
| EP4096671B1 (en) | Combination therapy for treating abnormal cell growth | |
| JP7578643B2 (ja) | 異常な細胞成長を処置するための方法および組成物 | |
| JP2019530706A5 (enExample) | ||
| JP6787792B2 (ja) | がんの処置のための併用治療 | |
| JP2019536805A5 (enExample) | ||
| KR20160066554A (ko) | 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료 | |
| JP2017506227A5 (enExample) | ||
| ES3036485T3 (en) | Combination comprising everolimus and amcenestrant | |
| ES2922378T3 (es) | C. novyi para el tratamiento de tumores sólidos en seres humanos | |
| JP2019516711A5 (enExample) | ||
| JP2014511383A5 (enExample) | ||
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| KR20190025733A (ko) | 원발성 호르몬 저항성 자궁내막암 및 유방암 치료 방법 및 약학적 조성물 | |
| JP2015517523A5 (enExample) | ||
| JP2019508476A5 (enExample) | ||
| RU2020122083A (ru) | Способ снижения ототоксичности у педиатрических пациентов, получающих химиотерапию препаратами платины | |
| AU2023336057A1 (en) | Dosage regimens of estrogen receptor degraders | |
| JP2021505669A5 (enExample) | ||
| JP2019501957A5 (enExample) | ||
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| JP2023550740A5 (enExample) | ||
| CN110545803A (zh) | 用于淋巴结阳性、早期、激素受体阳性、人表皮生长因子受体2阴性乳腺癌的辅助治疗的内分泌疗法和abemaciclib组合 | |
| JP2018522881A5 (enExample) |